Viridian Therapeutics, Inc.
VRDNViridian Therapeutics is a biopharmaceutical company dedicated to the discovery and development of best-in-class therapies for rare and autoimmune diseases.
Earnings
Next report
Nov 4, 2026 (in 2 months)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
Viridian Therapeutics is a biopharmaceutical company dedicated to the discovery and development of best-in-class therapies for rare and autoimmune diseases. The company focuses on optimizing validated biological pathways to improve upon existing treatments in terms of efficacy, safety, and dosing convenience. Their primary focus is on addressing unmet medical needs in conditions such as thyroid eye disease and various autoimmune disorders.
Viridian positions itself as a fast-follower and optimizer, targeting established pathways to create differentiated, more convenient, or more effective versions of existing therapies.
FAQ
- What is Viridian Therapeutics, Inc.'s market cap?
- Viridian Therapeutics, Inc. (VRDN) has a market capitalization of $2.5B and trades on NASDAQ.
- What is Viridian Therapeutics, Inc.'s revenue and profitability?
- Viridian Therapeutics, Inc. generated $71.1M in trailing twelve-month revenue with a net loss of $387.0M, representing a net margin of -544.1%. Gross margin stands at 36.3%, with free cash flow of -$335.0M. The latest reported period is Q2 2026.
- Who are Viridian Therapeutics, Inc.'s competitors?
- Viridian Therapeutics, Inc.'s key competitors include Immunovant, Inc., Amgen Inc., Fulcrum Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Viridian Therapeutics, Inc. headquartered?
- Viridian Therapeutics, Inc. is headquartered in United States of America and employs approximately 94 people. It has been publicly traded since 2014.
